Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Bruce I Sachs. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Bruce I Sachs har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:VRTX / Vertex Pharmaceuticals Incorporated | Director | 45 000 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Bruce I Sachs. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Bruce I Sachs som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 3 366 | 45 000 | 8,08 | 389,84 | 1 312 201 | 17 542 800 | |
2025-08-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 1 634 | 41 634 | 4,08 | 389,36 | 636 214 | 16 210 614 | |
2024-08-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 295 | 40 000 | −11,69 | 508,00 | −2 689 860 | 20 320 000 |
2024-08-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 5 295 | 45 295 | 13,24 | 125,71 | 665 634 | 5 694 034 | |
2024-05-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 073 | 40 000 | −15,03 | 448,00 | −3 168 704 | 17 920 000 |
2024-05-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 7 073 | 47 073 | 17,68 | 93,51 | 661 396 | 4 401 796 | |
2023-11-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −11 250 | 40 000 | −21,95 | 385,00 | −4 331 250 | 15 400 000 |
2023-11-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 11 250 | 51 250 | 28,12 | 127,54 | 1 434 825 | 6 536 425 | |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 842 | 40 000 | −8,76 | 357,29 | −1 372 708 | 14 291 600 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 711 | 43 842 | −11,53 | 356,75 | −2 037 399 | 15 640 634 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 697 | 49 553 | −3,31 | 355,54 | −603 351 | 17 618 074 |
2023-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 11 250 | 51 250 | 28,12 | 127,54 | 1 434 825 | 6 536 425 | |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
G - Gift | −1 210 | 40 000 | −2,94 | ||||
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −8 026 | 41 210 | −16,30 | 327,48 | −2 628 354 | 13 495 451 |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 357 | 49 236 | −17,38 | 326,46 | −3 381 146 | 16 073 585 |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 917 | 59 593 | −4,67 | 325,65 | −949 921 | 19 406 460 |
2023-04-14 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 21 300 | 62 510 | 51,69 | 72,14 | 1 536 582 | 4 509 471 | |
2023-02-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 41 210 | −2,83 | 325,01 | −390 012 | 13 393 662 |
2023-02-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 1 200 | 42 410 | 2,91 | 72,14 | 86 568 | 3 059 457 | |
2022-05-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 4 462 | 4 462 | |||||
2022-04-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 151 | 13 824 | 1,11 | 289,41 | 43 750 | 4 000 661 | |
2022-01-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 190 | 13 672 | 1,41 | 230,58 | 43 750 | 3 152 568 | |
2021-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 240 | 13 483 | 1,81 | 182,07 | 43 750 | 2 454 777 | |
2021-08-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 15 000 | 41 210 | 57,23 | 197,91 | 2 968 650 | 8 155 871 | |
2021-07-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 221 | 13 242 | 1,70 | 198,00 | 43 750 | 2 621 977 | |
2021-05-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 6 067 | 6 067 | |||||
2021-04-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 199 | 13 021 | 1,55 | 220,17 | 43 750 | 2 866 910 | |
2021-01-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 194 | 12 823 | 1,53 | 225,99 | 43 750 | 2 897 787 | |
2020-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 3 905 | 26 210 | 17,51 | 218,79 | 854 375 | 5 734 486 | |
2020-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 4 270 | 22 305 | 23,68 | 217,49 | 928 682 | 4 851 114 | |
2020-11-12 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
P - Purchase | 6 825 | 18 035 | 60,88 | 216,47 | 1 477 408 | 3 904 036 | |
2020-10-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 196 | 12 629 | 1,58 | 222,81 | 43 750 | 2 813 877 | |
2020-07-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 155 | 12 433 | 1,26 | 292,77 | 45 453 | 3 639 917 | |
2020-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 4 527 | 4 527 | |||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −22 500 | 0 | −100,00 | ||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −22 500 | 0 | −100,00 | ||||
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 960 | 11 210 | −20,89 | 272,46 | −806 482 | 3 054 277 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −6 232 | 14 170 | −30,55 | 271,63 | −1 692 798 | 3 848 997 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 889 | 20 402 | −22,40 | 270,49 | −1 592 916 | 5 518 537 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −15 751 | 26 291 | −37,46 | 269,53 | −4 245 367 | 7 086 213 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −11 568 | 42 042 | −21,58 | 268,65 | −3 107 743 | 11 294 583 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 600 | 53 610 | −4,63 | 267,50 | −695 500 | 14 340 675 |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 22 500 | 56 210 | 66,75 | 81,54 | 1 834 650 | 4 583 363 | |
2020-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 22 500 | 33 710 | 200,71 | 59,55 | 1 339 875 | 2 007 430 | |
2020-04-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 179 | 12 277 | 1,48 | 258,56 | 46 250 | 3 174 453 | |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −20 000 | 0 | −100,00 | ||||
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 11 210 | −0,88 | 235,40 | −23 540 | 2 638 834 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −900 | 11 310 | −7,37 | 234,15 | −210 735 | 2 648 236 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 800 | 12 210 | −12,85 | 233,13 | −419 634 | 2 846 517 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 14 010 | −7,89 | 232,04 | −278 448 | 3 250 880 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 15 210 | −7,31 | 230,87 | −277 044 | 3 511 533 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 16 410 | −2,96 | 229,90 | −114 950 | 3 772 659 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 16 910 | −3,43 | 228,33 | −136 998 | 3 861 060 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −300 | 17 510 | −1,68 | 227,66 | −68 298 | 3 986 327 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 644 | 17 810 | −24,06 | 227,01 | −1 281 244 | 4 043 048 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 198 | 23 454 | −15,18 | 226,32 | −950 091 | 5 308 109 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 858 | 27 652 | −6,30 | 224,98 | −418 013 | 6 221 147 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 700 | 29 510 | −5,45 | 224,02 | −380 834 | 6 610 830 |
2020-02-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 20 000 | 31 210 | 178,41 | 53,85 | 1 077 000 | 1 680 658 | |
2020-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 200 | 12 099 | 1,68 | 231,55 | 46 250 | 2 801 421 | |
2019-10-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 264 | 11 899 | 2,26 | 175,50 | 46 250 | 2 088 242 | |
2019-07-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 257 | 11 635 | 2,26 | 176,39 | 45 371 | 2 052 348 | |
2019-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 1 801 | 11 378 | 18,81 | ||||
2019-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 6 659 | 6 659 | |||||
2019-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
D - Sale to Issuer | −1 801 | 11 210 | −13,84 | ||||
2019-04-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 247 | 9 577 | 2,65 | 182,28 | 45 000 | 1 745 707 | |
2019-01-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 243 | 9 330 | 2,68 | 184,90 | 45 000 | 1 725 152 | |
2019-01-02 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
G - Gift | −10 000 | 13 011 | −43,46 | ||||
2018-12-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2018-12-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 23 011 | 76,86 | 34,24 | 342 400 | 787 897 | |
2018-10-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 251 | 9 087 | 2,84 | 179,29 | 45 000 | 1 629 175 | |
2018-07-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 249 | 8 836 | 2,90 | 180,97 | 45 000 | 1 599 019 | |
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 2 188 | 8 587 | 34,19 | ||||
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 3 229 | 3 229 | |||||
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
D - Sale to Issuer | −2 188 | 13 011 | −14,40 | ||||
2018-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 1 801 | 15 199 | 13,44 | ||||
2018-04-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 280 | 6 399 | 4,57 | 160,89 | 45 000 | 1 029 561 | |
2018-01-17 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 262 | 6 119 | 4,47 | 157,50 | 41 250 | 963 816 | |
2018-01-17 |
|
5 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
G - Gift | −10 000 | 13 398 | −42,74 | ||||
2017-10-18 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 265 | 5 858 | 4,75 | 155,44 | 41 250 | 910 500 | |
2017-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 317 | 5 592 | 6,01 | 130,15 | 41 250 | 727 823 | |
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 2 941 | 5 275 | 125,99 | ||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 5 295 | 5 295 | |||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
D - Sale to Issuer | −2 941 | 23 398 | −11,17 | ||||
2017-06-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 2 188 | 26 339 | 9,06 | ||||
2017-04-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 360 | 2 334 | 18,24 | 114,58 | 41 250 | 267 458 | |
2017-01-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 508 | 1 974 | 34,67 | 81,16 | 41 250 | 160 229 | |
2016-10-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 516 | 1 466 | 54,25 | 80,01 | 41 250 | 117 293 | |
2016-07-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 461 | 950 | 94,25 | 89,45 | 41 250 | 85 015 | |
2016-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (Right to Buy) |
A - Award | 7 073 | 7 073 | |||||
2016-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
A - Award | 2 941 | 24 151 | 13,87 | 0,01 | 29 | 242 | |
2016-04-19 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Deferred Stock Units |
A - Award | 489 | 489 | 87,60 | 42 860 | 42 860 | ||
2015-08-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2015-08-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 21 210 | −32,04 | 140,13 | −1 401 300 | 2 972 157 |
2015-08-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 34,24 | 342 400 | 1 068 630 | |
2015-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 | |||||
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 375 | 21 210 | −6,09 | 136,14 | −187 192 | 2 887 529 |
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −8 625 | 22 585 | −27,64 | 135,42 | −1 167 998 | 3 058 461 |
2015-03-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 29,89 | 298 900 | 932 867 | |
2015-03-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2015-03-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 21 210 | −32,04 | 130,13 | −1 301 300 | 2 760 057 |
2015-03-20 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 29,89 | 298 900 | 932 867 | |
2015-01-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −139 | 0 | −100,00 | ||||
2015-01-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −139 | 21 210 | −0,65 | 125,00 | −17 375 | 2 651 250 |
2015-01-22 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 139 | 21 349 | 0,66 | 28,40 | 3 948 | 606 312 | |
2015-01-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −9 861 | 139 | −98,61 | ||||
2015-01-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −9 861 | 21 210 | −31,74 | 125,04 | −1 233 019 | 2 652 098 |
2015-01-13 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 9 861 | 31 071 | 46,49 | 28,40 | 280 052 | 882 416 | |
2014-12-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2014-12-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −10 000 | 21 210 | −32,04 | 120,03 | −1 200 300 | 2 545 836 |
2014-12-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 28,40 | 284 000 | 886 364 | |
2014-11-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −9 900 | 0 | −100,00 | ||||
2014-11-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −9 900 | 21 210 | −31,82 | 115,21 | −1 140 579 | 2 443 604 |
2014-11-07 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 9 900 | 31 110 | 46,68 | 29,84 | 295 416 | 928 322 | |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −100 | 9 900 | −1,00 | ||||
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 21 210 | −0,47 | 111,86 | −11 186 | 2 372 551 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 100 | 21 310 | 0,47 | 29,84 | 2 984 | 635 890 | |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −10 000 | 10 000 | −50,00 | ||||
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −100 | 21 210 | −0,47 | 115,45 | −11 545 | 2 448 694 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 400 | 21 310 | −17,11 | 114,23 | −502 612 | 2 434 241 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 200 | 25 710 | −11,07 | 113,47 | −363 104 | 2 917 314 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 300 | 28 910 | −7,37 | 112,47 | −258 681 | 3 251 508 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 10 000 | 31 210 | 47,15 | 29,84 | 298 400 | 931 306 | |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option (right to buy) |
M - Exercise | −20 000 | 0 | −100,00 | ||||
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 684 | 21 210 | −11,23 | 112,80 | −302 755 | 2 392 488 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −17 316 | 23 894 | −42,02 | 112,03 | −1 939 911 | 2 676 845 |
2014-11-05 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
M - Exercise | 20 000 | 41 210 | 94,30 | 34,32 | 686 400 | 1 414 327 | |
2014-06-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 | |||||
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −500 | 21 210 | −2,30 | 76,57 | −38 285 | 1 624 050 |
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 000 | 21 710 | −12,14 | 75,25 | −225 750 | 1 633 678 |
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 750 | 24 710 | −10,01 | 74,47 | −204 792 | 1 840 154 |
2014-03-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 450 | 27 460 | −8,19 | 73,53 | −180 148 | 2 019 134 |
2014-02-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 200 | 29 910 | −9,66 | 84,13 | −269 216 | 2 516 328 |
2014-02-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −3 800 | 33 110 | −10,30 | 83,65 | −317 870 | 2 769 652 |
2014-02-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 300 | 36 910 | −3,40 | 82,51 | −107 263 | 3 045 444 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −400 | 38 210 | −1,04 | 86,91 | −34 764 | 3 320 831 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 500 | 38 610 | −3,74 | 85,87 | −128 805 | 3 315 441 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 40 110 | −1,47 | 84,90 | −50 940 | 3 405 339 |
2014-01-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 800 | 40 710 | −12,47 | 83,89 | −486 562 | 3 415 162 |
2013-12-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 200 | 46 510 | −2,52 | 73,45 | −88 140 | 3 416 160 |
2013-12-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 100 | 47 710 | −12,95 | 72,95 | −517 945 | 3 480 444 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −200 | 54 810 | −0,36 | 67,15 | −13 430 | 3 680 492 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 700 | 55 010 | −3,00 | 66,25 | −112 625 | 3 644 412 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 900 | 56 710 | −7,95 | 65,35 | −320 215 | 3 705 998 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −800 | 61 610 | −1,28 | 64,21 | −51 368 | 3 955 978 |
2013-11-21 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −700 | 62 410 | −1,11 | 63,10 | −44 170 | 3 938 071 |
2013-10-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 800 | 63 110 | −8,42 | 77,17 | −447 586 | 4 870 199 |
2013-10-25 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 500 | 68 910 | −3,50 | 76,80 | −192 000 | 5 292 288 |
2013-09-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 500 | 71 410 | −3,38 | 75,23 | −188 075 | 5 372 174 |
2013-09-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 800 | 73 910 | −7,28 | 74,86 | −434 188 | 5 532 903 |
2013-09-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 79 710 | −0,75 | 77,97 | −46 782 | 6 214 989 |
2013-09-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −6 010 | 80 310 | −6,96 | 77,29 | −464 513 | 6 207 160 |
2013-09-03 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 690 | 86 320 | −1,92 | 76,55 | −129 370 | 6 607 796 |
2013-07-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −600 | 88 010 | −0,68 | 87,03 | −52 218 | 7 659 510 |
2013-07-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 700 | 88 610 | −2,96 | 85,89 | −231 903 | 7 610 713 |
2013-07-26 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −5 000 | 91 310 | −5,19 | 85,10 | −425 500 | 7 770 481 |
2013-06-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 700 | 96 310 | −2,73 | 76,53 | −206 631 | 7 370 604 |
2013-06-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 500 | 99 010 | −4,35 | 75,85 | −341 325 | 7 509 908 |
2013-06-24 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 100 | 103 510 | −1,05 | 74,81 | −82 291 | 7 743 583 |
2013-06-04 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 | |||||
2013-05-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −4 262 | 104 610 | −3,91 | 80,63 | −343 645 | 8 434 704 |
2013-05-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 538 | 108 872 | −1,39 | 79,50 | −122 271 | 8 655 324 |
2013-05-23 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −2 500 | 110 410 | −2,21 | 78,48 | −196 200 | 8 664 977 |
2013-05-16 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | −60 000 | 112 910 | −34,70 | 81,15 | −4 869 000 | 9 162 646 | |
2013-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −7 000 | 172 910 | −3,89 | 77,41 | −541 870 | 13 384 963 |
2013-05-08 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Common Stock |
S - Sale | X | −1 300 | 179 910 | −0,72 | 76,19 | −99 047 | 13 707 343 |
2012-06-01 |
|
4 | VRTX |
VERTEX PHARMACEUTICALS INC / MA
Stock Option |
A - Award | 22 500 | 22 500 |